REMAP-CAP Trial

All Done!

A bit more to do?    Log in


7 Design methods for randomisation

Randomisation is at the heart of clinical trials, ensuring fairness and reducing bias when assigning participants to treatment groups.

There’s no one-size-fits-all approach—different methods are used depending on the trial’s design and objectives. Some aim for simplicity, while others focus on balancing key characteristics or adapting as new data emerges. The right choice helps maintain statistical integrity and optimises patient outcomes.

At Spiral, we work with a range of randomisation methods, making sure trials run smoothly and deliver reliable results.

Read more on our blog and get in touch for more »




 

REMAP-CAP

REMAP-CAP is a Randomized, Embedded, Multifactorial Adaptive Platform trial for hospitalised patients with respiratory tract infections, including COVID-19. The aim of this global trial is to efficiently evaluate a range of interventions to improve outcomes for patients.

About the software

This is Spinnaker, a user friendly, bespoke application that helps researchers find answers to important medical questions. The team behind the platform can adapt the software to match your study and we are especially interested in doing this for novel trials.

Spinnaker is a cloud based, integrated software/database solution for randomising patients using any design methodology including response adaptive methods; backed up by an electronic data capture application that is intuitive and particular. The application also includes management functions to alert relevant people about events (e.g. SAE), to manage drug inventory and to report on progress.

You can read more on the Spinnaker website or contact Audrey on [email protected]

You can get to know us a little better through our blog and social media pages accessed via the logout screen of this trial.

Made with love in New Zealand.